<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590915</url>
  </required_header>
  <id_info>
    <org_study_id>Erwinase</org_study_id>
    <secondary_id>IND-290</secondary_id>
    <nct_id>NCT00590915</nct_id>
    <nct_alias>NCT01009164</nct_alias>
  </id_info>
  <brief_title>Erwinase Master Treatment Protocol</brief_title>
  <acronym>EMTP</acronym>
  <official_title>Erwinase Master Treatment Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fisher Bioservices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Phoenix Children's Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to make Erwinase available to patients with acute lymphoblastic
      leukemia (ALL) who have had previous allergic reactions to certain formulations of
      L-asparaginase.
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Leukemia, Acute Lymphoblastic</condition>
  <condition>Acute Lymphoid Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erwinia L-asparaginase</intervention_name>
    <description>Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.
NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics.</description>
    <other_name>Erwinase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must give written informed consent to receive Erwinase.

          -  Patient must be treated for acute lymphoblastic leukemia.

          -  Patient must have either systemic hypersensitivity reactions to native (Elspar) or
             pegylated E.coli asparaginase (Oncaspar). This includes patients with generalized rash
             with or without anaphylactic symptoms, or patients with previously documented local or
             systemic reactions to E.coli derived L-asparaginase.

        Exclusion Criteria:

          -  Previous allergic reaction to Erwinia L-asparaginase (Erwinase)

          -  Previous acute pancreatitis

          -  Pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <link>
    <url>http://www.phoenixchildrens.com</url>
    <description>Phoenix Children's Hospital</description>
  </link>
  <link>
    <url>http://www.eusapharma.com</url>
    <description>EUSA Pharma (US), Inc.- manufacturer of Erwinase</description>
  </link>
  <link>
    <url>http://www.fisherbioservices.com/</url>
    <description>Fisher BioServices - U.S. distributor for Erwinase</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>April 11, 2012</last_update_submitted>
  <last_update_submitted_qc>April 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <name_title>Jessica Boklan, MD/Director, Oncology Research</name_title>
    <organization>Phoenix Children's Hospital</organization>
  </responsible_party>
  <keyword>ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asparaginase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

